Is This the Death of Versartis?
Versartis shares absolutely cratered on Friday after the firm announced results from its late-stage Velocity clinical trial of somavaratan in pediatric growth hormone deficiency.
All Work
Chris Lange
Is It Time for a Turnaround at Finish Line?
After Finish Line reported its fiscal second-quarter financial results before the markets opened on Friday, shares rose handily.
Thursday’s Biggest Winners and Losers in the S&P 500
Thursday was a down day for the U.S. broad markets with all averages pulling back from their all-time highs. Crude oil didn’t do too much on the day and oil & gas stocks had…
FDA Crashes Down on Intercept’s Deadly Drug
As we have said before, updates from the FDA have the potential to make or break a company. In this case it seems like a mild setback, but further complications could prove to be…
Why Jefferies Sees AMD Rising 40%
Some might think the run at AMD is over, or that shares might slow down after a rally like this, but one analyst is continuing to take a bullish stance on the stock.
Can Snap’s Newest Partner Stop Shares From Falling?
To say that this social media company’s shares are struggling might be an understatement. However with this new partnership Snap is looking to pull in some more ad revenue.
How Harry Potter Killed Scholastic Shares
Scholastic released its most recent quarterly results before the markets opened on Thursday. Looking at the numbers year over year, there is a huge disparity, and a reason behind it.
Can BioCryst Turn Itself Around With This FDA Approval?
BioCryst Pharmaceuticals has received an update from the FDA. This approval is very welcome as BioCryst has been underperforming the market so far this year.
Zai Lab Announces Potential Pricing for IPO
Biopharmaceutical company Zai Lab intends to price its 8 million shares in the range that results in an initial public offering valued up to more than $165 million.
Wednesday’s Biggest Winners and Losers in the S&P 500
Wednesday was a relatively flat day for the broad U.S. markets with two out of the three major averages hitting new all-time highs in the session. Crude oil was up on the day and…
Why Alnylam Pharmaceuticals Is Wednesday’s Top Stock
Alnylam Pharmaceuticals saw its shares make a handy gain on Wednesday after the firm gave an update on its late-stage trial in patients with hereditary ATTR amyloidosis with polyneuropathy.
Best Enters the Market With a Bang
Chinese logistics firm Best entered the market with a bang on Wednesday, the largest IPO by a Chinese firm in the United States in almost a year.
Why Record Revenues Aren’t Enough for Adobe Investors
Adobe Systems released its most recent quarterly results after the markets closed on Tuesday and investors were not happy.
Is Bed Bath & Beyond Surrendering to the Amazon Effect?
Bed Bath & Beyond saw its shares fall on Wednesday after the company issued its most recent earnings report.
Why FedEx Is Taking a Step Back After Earnings
FedEx reported disappointing fiscal first-quarter earnings after the markets closed on Tuesday and lowered its guidance.
Tuesday’s Biggest Winners and Losers in the S&P 500
Tuesday was another positive day for the U.S. broad markets with all three major averages hitting new all-time highs in the session. Crude oil was lower on the day and Oil & Gas stocks…
What to Expect When FedEx Reports After the Close
FedEx is scheduled to release its most recent quarterly results after the markets close on Tuesday.
Sprint and T-Mobile Reportedly in Active Merger Talks
Both Sprint and T-Mobile shares made handy gains on Tuesday after it came to light that these major telecom players were actively in merger talks.
MediWound Secondary Capitalizes on 2017 Success
Biotech companies may attempt a secondary offering after seeing a run in the share price. So now seems the as good a time as any for MediWound to capitalize in 2017.
Why Synchronoss Shares Are Getting Crushed
Synchronoss Technologies saw its shares take a big step back, almost touching a multiyear low, after the firm provided an update on its strategic alternatives.